Annual CFO
-$19.00 M
+$86.00 K+0.45%
31 December 2023
Summary:
Theriva Biologics annual cash flow from operations is currently -$19.00 million, with the most recent change of +$86.00 thousand (+0.45%) on 31 December 2023. During the last 3 years, it has fallen by -$6.83 million (-56.11%). TOVX annual CFO is now -1655.48% below its all-time high of -$1.08 million, reached on 01 December 2005.TOVX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$3.91 M
-$461.00 K-13.35%
01 September 2024
Summary:
Theriva Biologics quarterly cash flow from operations is currently -$3.91 million, with the most recent change of -$461.00 thousand (-13.35%) on 01 September 2024. Over the past year, it has dropped by -$960.00 thousand (-32.51%). TOVX quarterly CFO is now -182.23% below its all-time high of $4.76 million, reached on 01 June 2001.TOVX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$18.79 M
-$960.00 K-5.39%
01 September 2024
Summary:
Theriva Biologics TTM cash flow from operations is currently -$18.79 million, with the most recent change of -$960.00 thousand (-5.39%) on 01 September 2024. Over the past year, it has dropped by -$964.00 thousand (-5.41%). TOVX TTM CFO is now -4596.75% below its all-time high of -$400.00 thousand, reached on 01 March 1993.TOVX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TOVX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.5% | -32.5% | -5.4% |
| 3 y3 years | -56.1% | +18.6% | -45.8% |
| 5 y5 years | -36.9% | -8.5% | -35.4% |
TOVX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -56.1% | +0.5% | -32.5% | +40.2% | -45.8% | +5.1% |
| 5 y | 5 years | -56.1% | +0.5% | -93.1% | +40.2% | -78.3% | +5.1% |
| alltime | all time | -1655.5% | +51.1% | -182.2% | +74.8% | -4596.8% | +52.0% |
Theriva Biologics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.91 M(+13.4%) | -$18.79 M(+5.4%) |
| June 2024 | - | -$3.45 M(-29.3%) | -$17.83 M(-2.4%) |
| Mar 2024 | - | -$4.88 M(-25.4%) | -$18.27 M(-3.8%) |
| Dec 2023 | -$19.00 M(-0.5%) | -$6.54 M(+121.5%) | -$19.00 M(+6.6%) |
| Sept 2023 | - | -$2.95 M(-24.1%) | -$17.82 M(-7.8%) |
| June 2023 | - | -$3.89 M(-30.6%) | -$19.33 M(-2.3%) |
| Mar 2023 | - | -$5.61 M(+4.5%) | -$19.79 M(+3.7%) |
| Dec 2022 | -$19.08 M(+48.0%) | -$5.37 M(+20.5%) | -$19.08 M(+3.0%) |
| Sept 2022 | - | -$4.46 M(+2.3%) | -$18.52 M(+14.2%) |
| June 2022 | - | -$4.36 M(-11.1%) | -$16.22 M(+12.2%) |
| Mar 2022 | - | -$4.90 M(+1.9%) | -$14.46 M(+12.2%) |
| Dec 2021 | -$12.89 M(+5.9%) | - | - |
| Dec 2021 | - | -$4.81 M(+123.1%) | -$12.89 M(+15.0%) |
| Sept 2021 | - | -$2.16 M(-16.9%) | -$11.21 M(+1.0%) |
| June 2021 | - | -$2.60 M(-22.0%) | -$11.11 M(+5.4%) |
| Mar 2021 | - | -$3.33 M(+6.3%) | -$10.54 M(-13.4%) |
| Dec 2020 | -$12.17 M(-12.3%) | -$3.13 M(+52.8%) | -$12.17 M(-3.7%) |
| Sept 2020 | - | -$2.05 M(+1.2%) | -$12.64 M(-7.4%) |
| June 2020 | - | -$2.03 M(-59.2%) | -$13.65 M(-6.5%) |
| Mar 2020 | - | -$4.96 M(+37.6%) | -$14.61 M(+5.3%) |
| Dec 2019 | -$13.87 M(-19.7%) | -$3.60 M(+17.7%) | -$13.87 M(+2.3%) |
| Sept 2019 | - | -$3.06 M(+2.7%) | -$13.56 M(-3.8%) |
| June 2019 | - | -$2.98 M(-29.4%) | -$14.10 M(-8.6%) |
| Mar 2019 | - | -$4.22 M(+28.4%) | -$15.42 M(-10.7%) |
| Dec 2018 | -$17.28 M(-14.5%) | -$3.29 M(-8.7%) | -$17.28 M(-3.6%) |
| Sept 2018 | - | -$3.60 M(-16.4%) | -$17.92 M(-4.9%) |
| June 2018 | - | -$4.31 M(-29.1%) | -$18.84 M(-7.1%) |
| Mar 2018 | - | -$6.08 M(+54.6%) | -$20.27 M(+0.4%) |
| Dec 2017 | -$20.20 M(-27.6%) | -$3.93 M(-13.1%) | -$20.20 M(-24.2%) |
| Sept 2017 | - | -$4.52 M(-21.2%) | -$26.66 M(-5.2%) |
| June 2017 | - | -$5.74 M(-4.5%) | -$28.11 M(-0.4%) |
| Mar 2017 | - | -$6.01 M(-42.1%) | -$28.23 M(+1.2%) |
| Dec 2016 | -$27.90 M(-28.3%) | -$10.38 M(+73.6%) | -$27.90 M(-2.1%) |
| Sept 2016 | - | -$5.98 M(+2.1%) | -$28.49 M(-24.5%) |
| June 2016 | - | -$5.86 M(+3.3%) | -$37.72 M(-3.6%) |
| Mar 2016 | - | -$5.67 M(-48.3%) | -$39.11 M(+0.6%) |
| Dec 2015 | -$38.89 M(+141.9%) | -$10.97 M(-27.9%) | -$38.89 M(+18.9%) |
| Sept 2015 | - | -$15.21 M(+109.8%) | -$32.70 M(+48.5%) |
| June 2015 | - | -$7.25 M(+32.8%) | -$22.02 M(+21.9%) |
| Mar 2015 | - | -$5.46 M(+14.2%) | -$18.07 M(+12.4%) |
| Dec 2014 | -$16.08 M(+108.3%) | -$4.78 M(+5.4%) | -$16.08 M(+14.8%) |
| Sept 2014 | - | -$4.54 M(+37.6%) | -$14.00 M(+25.2%) |
| June 2014 | - | -$3.29 M(-5.0%) | -$11.19 M(+17.4%) |
| Mar 2014 | - | -$3.47 M(+28.3%) | -$9.53 M(+23.4%) |
| Dec 2013 | -$7.72 M(-13.4%) | -$2.70 M(+57.2%) | -$7.72 M(-21.1%) |
| Sept 2013 | - | -$1.72 M(+5.3%) | -$9.79 M(+2.9%) |
| June 2013 | - | -$1.63 M(-1.7%) | -$9.51 M(+3.8%) |
| Mar 2013 | - | -$1.66 M(-65.2%) | -$9.16 M(+2.8%) |
| Dec 2012 | -$8.92 M(+210.1%) | -$4.77 M(+231.0%) | -$8.92 M(+82.9%) |
| Sept 2012 | - | -$1.44 M(+12.1%) | -$4.87 M(+12.2%) |
| June 2012 | - | -$1.29 M(-9.1%) | -$4.34 M(+8.3%) |
| Mar 2012 | - | -$1.42 M(+93.6%) | -$4.01 M(+39.4%) |
| Dec 2011 | -$2.88 M(+151.1%) | -$731.00 K(-19.8%) | -$2.88 M(+2.3%) |
| Sept 2011 | - | -$911.00 K(-4.3%) | -$2.81 M(+0.5%) |
| June 2011 | - | -$952.00 K(+238.8%) | -$2.79 M(+368.7%) |
| Mar 2011 | - | -$281.00 K(-57.8%) | -$596.20 K(-47.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$1.15 M(-60.8%) | -$665.20 K(-25.8%) | -$1.15 M(-7.3%) |
| Sept 2010 | - | -$895.90 K(-171.9%) | -$1.24 M(+18.4%) |
| June 2010 | - | $1.25 M(-250.1%) | -$1.04 M(-67.2%) |
| Mar 2010 | - | -$829.80 K(+9.8%) | -$3.18 M(+9.0%) |
| Dec 2009 | -$2.92 M(-39.8%) | -$755.50 K(+7.3%) | -$2.92 M(+1.5%) |
| Sept 2009 | - | -$704.30 K(-21.0%) | -$2.87 M(-9.9%) |
| June 2009 | - | -$891.70 K(+57.2%) | -$3.19 M(-11.6%) |
| Mar 2009 | - | -$567.30 K(-20.3%) | -$3.61 M(-25.7%) |
| Dec 2008 | -$4.85 M(-26.6%) | -$711.50 K(-30.1%) | -$4.85 M(-23.8%) |
| Sept 2008 | - | -$1.02 M(-22.2%) | -$6.37 M(-12.4%) |
| June 2008 | - | -$1.31 M(-27.8%) | -$7.27 M(+10.0%) |
| Mar 2008 | - | -$1.81 M(-18.6%) | -$6.60 M(-0.0%) |
| Dec 2007 | -$6.61 M(+179.3%) | -$2.23 M(+16.0%) | -$6.61 M(+32.0%) |
| Sept 2007 | - | -$1.92 M(+197.2%) | -$5.00 M(+33.7%) |
| June 2007 | - | -$645.80 K(-64.4%) | -$3.74 M(+2.2%) |
| Mar 2007 | - | -$1.81 M(+190.8%) | -$3.66 M(+54.8%) |
| Dec 2006 | -$2.37 M(+118.6%) | -$624.00 K(-5.0%) | -$2.37 M(+35.8%) |
| Sept 2006 | - | -$657.00 K(+16.2%) | -$1.74 M(+60.6%) |
| June 2006 | - | -$565.60 K(+8.9%) | -$1.08 M(+108.9%) |
| Mar 2006 | - | -$519.20 K(+10.0%) | -$519.20 K(-88.5%) |
| Dec 2005 | -$1.08 M(-81.4%) | - | - |
| Mar 2003 | - | -$471.80 K(+27.9%) | -$4.51 M(-22.6%) |
| Dec 2002 | -$5.82 M(-27.8%) | -$368.80 K(-62.4%) | -$5.82 M(-27.8%) |
| Sept 2002 | - | -$980.60 K(-63.5%) | -$8.07 M(-17.1%) |
| June 2002 | - | -$2.69 M(+50.5%) | -$9.73 M(+326.0%) |
| Mar 2002 | - | -$1.79 M(-31.7%) | -$2.28 M(-71.7%) |
| Dec 2001 | -$8.07 M(+42.9%) | -$2.62 M(-1.0%) | -$8.07 M(+24.2%) |
| Sept 2001 | - | -$2.64 M(-155.5%) | -$6.49 M(+26.1%) |
| June 2001 | - | $4.76 M(-162.9%) | -$5.15 M(-54.8%) |
| Mar 2001 | - | -$7.57 M(+625.8%) | -$11.40 M(+101.8%) |
| Dec 2000 | -$5.65 M(-65.0%) | -$1.04 M(-19.5%) | -$5.65 M(-68.0%) |
| Sept 2000 | - | -$1.30 M(-13.0%) | -$17.65 M(-1.1%) |
| June 2000 | - | -$1.49 M(-18.1%) | -$17.85 M(+5.8%) |
| Mar 2000 | - | -$1.82 M(-86.1%) | -$16.87 M(+4.5%) |
| Dec 1999 | -$16.14 M(-13.7%) | -$13.04 M(+769.6%) | -$16.14 M(+324.8%) |
| Sept 1999 | - | -$1.50 M(+195.6%) | -$3.80 M(-11.6%) |
| June 1999 | - | -$507.40 K(-53.6%) | -$4.30 M(-77.7%) |
| Mar 1999 | - | -$1.09 M(+56.1%) | -$19.29 M(+3.2%) |
| Dec 1998 | -$18.70 M(+179.1%) | -$700.00 K(-65.0%) | -$18.70 M(0.0%) |
| Sept 1998 | - | -$2.00 M(-87.1%) | -$18.70 M(+3.3%) |
| June 1998 | - | -$15.50 M(+3000.0%) | -$18.10 M(+262.0%) |
| Mar 1998 | - | -$500.00 K(-28.6%) | -$5.00 M(-25.4%) |
| Dec 1997 | -$6.70 M(+11.7%) | -$700.00 K(-50.0%) | -$6.70 M(-8.2%) |
| Sept 1997 | - | -$1.40 M(-41.7%) | -$7.30 M(-3.9%) |
| June 1997 | - | -$2.40 M(+9.1%) | -$7.60 M(+16.9%) |
| Mar 1997 | - | -$2.20 M(+69.2%) | -$6.50 M(+8.3%) |
| Dec 1996 | -$6.00 M(-20.0%) | -$1.30 M(-23.5%) | -$6.00 M(+27.7%) |
| Sept 1996 | - | -$1.70 M(+30.8%) | -$4.70 M(+56.7%) |
| June 1996 | - | -$1.30 M(-23.5%) | -$3.00 M(+76.5%) |
| Mar 1996 | - | -$1.70 M(+325.0%) | -$1.70 M(-51.4%) |
| Dec 1995 | -$7.50 M(+66.7%) | - | - |
| Dec 1994 | -$4.50 M(+28.6%) | - | - |
| Mar 1994 | - | -$400.00 K(-150.0%) | -$3.50 M(0.0%) |
| Dec 1993 | -$3.50 M | $800.00 K(-123.5%) | -$3.50 M(-18.6%) |
| Sept 1993 | - | -$3.40 M(+580.0%) | -$4.30 M(+377.8%) |
| June 1993 | - | -$500.00 K(+25.0%) | -$900.00 K(+125.0%) |
| Mar 1993 | - | -$400.00 K | -$400.00 K |
FAQ
- What is Theriva Biologics annual cash flow from operations?
- What is the all time high annual CFO for Theriva Biologics?
- What is Theriva Biologics annual CFO year-on-year change?
- What is Theriva Biologics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Theriva Biologics?
- What is Theriva Biologics quarterly CFO year-on-year change?
- What is Theriva Biologics TTM cash flow from operations?
- What is the all time high TTM CFO for Theriva Biologics?
- What is Theriva Biologics TTM CFO year-on-year change?
What is Theriva Biologics annual cash flow from operations?
The current annual CFO of TOVX is -$19.00 M
What is the all time high annual CFO for Theriva Biologics?
Theriva Biologics all-time high annual cash flow from operations is -$1.08 M
What is Theriva Biologics annual CFO year-on-year change?
Over the past year, TOVX annual cash flow from operations has changed by +$86.00 K (+0.45%)
What is Theriva Biologics quarterly cash flow from operations?
The current quarterly CFO of TOVX is -$3.91 M
What is the all time high quarterly CFO for Theriva Biologics?
Theriva Biologics all-time high quarterly cash flow from operations is $4.76 M
What is Theriva Biologics quarterly CFO year-on-year change?
Over the past year, TOVX quarterly cash flow from operations has changed by -$960.00 K (-32.51%)
What is Theriva Biologics TTM cash flow from operations?
The current TTM CFO of TOVX is -$18.79 M
What is the all time high TTM CFO for Theriva Biologics?
Theriva Biologics all-time high TTM cash flow from operations is -$400.00 K
What is Theriva Biologics TTM CFO year-on-year change?
Over the past year, TOVX TTM cash flow from operations has changed by -$964.00 K (-5.41%)